-  Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) -  Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p

Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases,

PALO ALTO, Calif. , Nov. 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management